Pan-cyclin-dependent kinase inhibition is a potential treatment for adenoid cystic carcinoma that downregulates the MYB::NFIB fusion and induces tumor regression

Junchi Huang; Peter Larsson; Maryam Kakay Afshari; Paloma Tejera Nevado; Tajana Tešan Tomić; André Fehr; Fredrik Jäwert; Göran Stenman; Mattias K. Andersson

doi:10.1002/cac2.70079

Cancer Communications ›› 2025, Vol. 45 ›› Issue (12) :1734 -1738. DOI: 10.1002/cac2.70079

LETTER TO THE JOURNAL

Pan-cyclin-dependent kinase inhibition is a potential treatment for adenoid cystic carcinoma that downregulates the MYB::NFIB fusion and induces tumor regression

Author information +

History +

PDF

Cite this article

Download citation ▾

Junchi Huang, Peter Larsson, Maryam Kakay Afshari, Paloma Tejera Nevado, Tajana Tešan Tomić, André Fehr, Fredrik Jäwert, Göran Stenman, Mattias K. Andersson. Pan-cyclin-dependent kinase inhibition is a potential treatment for adenoid cystic carcinoma that downregulates the MYB::NFIB fusion and induces tumor regression. Cancer Communications, 2025, 45(12): 1734-1738 DOI:10.1002/cac2.70079

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Inagaki H, Faquin WC, Stenman G, Urano M. Adenoid cystic carcinoma. In: The WHO Classification of Tumours Editorial Board. WHO Classification of Tumours. 5th Edition. Head and Neck Tumours. 9. Lyon: International Agency for Research on Cancer; 2024. p. 204-6.

[2]	Persson M, Andersson MK, Sahlin PE, Mitani Y, Brandwein-Weber MS, Frierson HF, et al. Comprehensive molecular characterization of adenoid cystic carcinoma reveals tumor suppressors as novel drivers and prognostic biomarkers. J Pathol. 2023;261(3):256-68.

[3]	Persson M, Andren Y, Mark J, Horlings HM, Persson F, Stenman G. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci U S A. 2009;106(44):18740-4.

[4]	Ho AS, Kannan K, Roy DM, Morris LG, Ganly I, Katabi N, et al. The mutational landscape of adenoid cystic carcinoma. Nat Genet. 2013;45(7):791-8.

[5]	Andersson MK, Afshari MK, Andren Y, Wick MJ, Stenman G. Targeting the Oncogenic Transcriptional Regulator MYB in Adenoid Cystic Carcinoma by Inhibition of IGF1R/AKT Signaling. J Natl Cancer Inst. 2017;109(9):djx017.

[6]	Persson M, Andersson MK, Mitani Y, Brandwein-Weber MS, Frierson HF, Moskaluk C, et al. Rearrangements, Expression, and Clinical Significance of MYB and MYBL1 in Adenoid Cystic Carcinoma: A Multi-Institutional Study. Cancers (Basel). 2022;14(15):3619.

[7]	Andersson MK, Mangiapane G, Nevado PT, Tsakaneli A, Carlsson T, Corda G, et al. ATR is a MYB regulated gene and potential therapeutic target in adenoid cystic carcinoma. Oncogenesis. 2020;9(1):5.

[8]	Yusenko MV, Biyanee A, Andersson MK, Radetzki S, von Kries JP, Stenman G, et al. Proteasome inhibitors suppress MYB oncogenic activity in a p300-dependent manner. Cancer Lett. 2021;520:132-42.

[9]	Huang J, Fehr A, Jawert F, Nilsson JA, Morris LGT, Stenman G, et al. MYB alternative promoter activity is increased in adenoid cystic carcinoma metastases and is associated with a specific gene expression signature. Oral Oncol. 2024;151:106763.